ACM
RLMD icon

ADAR1 Capital Management’s Relmada Therapeutics RLMD Stock Holding History

ADAR1 Capital Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.15M Buy
451,918
+421,052
+1,364% +$1.99M 0.19% 104
2025
Q4 		$149K Buy
+30,866
New +$103K 0.01% 235
2025
Q3 		– Sell
-130,000
Closed -$78K – 252
2025
Q2 		$78K Buy
+130,000
New +$66.7K 0.01% 184
2024
Q3 		– Sell
-50,601
Closed -$152K – 331
2024
Q2 		$152K Buy
50,601
+50,000
+8,319% +$181K 0.03% 154
2024
Q1 		$2.79K Sell
601
-58,000
-99% -$279K ﹤0.01% 245
2023
Q4 		$243K Buy
+58,601
New +$174K 0.09% 79

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

ADAR1 Capital Management's RLMD Position: Q1 2026 in Review

ADAR1 Capital Management increased its Relmada Therapeutics (RLMD) stake by 1,364% in Q1 2026, buying an estimated $1.99M and bringing the position to 451,918 shares worth $3.15M. The position accounts for 0.19% of the portfolio, ranked #104.

ADAR1 Capital Management first reported a position in RLMD in Q4 2023 and has held it in 6 quarters since. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • ADAR1 Capital Management held 451,918 shares of Relmada Therapeutics worth $3.15M as of Q1 2026.
  • ADAR1 Capital Management bought 421,052 Relmada Therapeutics shares in Q1 2026, an estimated $1.99M.
  • Relmada Therapeutics made up 0.19% of ADAR1 Capital Management's portfolio in Q1 2026, its #104 holding.
  • ADAR1 Capital Management first reported a position in Relmada Therapeutics in Q4 2023 and has held it in 6 quarters since.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.